Esther C. van den Broek

Author

Also Known As

E C van den Broek, E. C. van den Broek, E.C. Van den Broek, E.C. van den Broek, Esther C van den Broek, Esther C. Van den Broek, Esther C. van den Broek

Publications

967

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Erasmus University Rotterdam Netherlands Comprehensive Cancer Organisation Jeroen Bosch Ziekenhuis Maasstad Ziekenhuis

About

Esther C. van den Broek is an author at Erasmus MC specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	250
2	Health Sciences	1	1	13
3	Cell Biology	1	1	60
4	Epidemiology	1	1	13
5	Health Policy	1	1	32

Esther C. van den Broek

Publications

930

Citations

H-Index

Page 1

	Year	Citations
Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome Jules L. Derks, Noémie Leblay, Erik Thunnissen, Clinical Cancer Research	2017	216
Salivary gland pleomorphic adenoma in the Netherlands: A nationwide observational study of primary tumor incidence, malignant transformation, recurrence, and risk factors for recurrence Matthijs H. Valstar, Mischa de Ridder, Esther C. van den Broek, Oral Oncology	2017	139
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Jules L. Derks, Robert Jan van Suylen, Erik Thunnissen, European Respiratory Journal	2017	113
Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study Shusma C. Doebar, Esther C. van den Broek, Linetta B. Koppert, Breast Cancer Research and Treatment	2016	67
DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile B.C.M. Hermans, Jules L. Derks, Erik Thunnissen, Lung Cancer Molecular SubtypesGliomaNeuroendocrine ProfileMedicinePathology	2019	60
Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study Lieske H. Schrijver, Antonis C Antoniou, Håkan Olsson, American Journal of Obstetrics and Gynecology	2021	56
Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry Simone Oerlemans, Djamila E. Issa, Esther C. van den Broek, Annals of Hematology Hematological MalignancyLymphoid NeoplasiaHealth-related QualityMedicineImmunology	2014	48
Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens? Jules L. Derks, Anne‐Marie C. Dingemans, Robert‐Jan van Suylen, Histopathology	2018	45
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC) B.C.M. Hermans, Jules L. Derks, Erik Thunnissen, Lung Cancer Endocrine OncologyMolecular SubtypesPd-l1 ExpressionMedicinePrognostic Value	2019	41
Chronic Lymphocytic Leukaemia in the Netherlands: Trends in incidence, treatment and survival, 1989–2008 Esther C. van den Broek, Arnon P. Kater, S.A.M. van de Schans, European Journal of Cancer Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineClinical Epidemiology	2011	34

Page 1